Department of Anesthesiology, China-Japan Union Hospital of Jilin University, No. 126, Xiantai Rd, Changchun, 130000, China.
BMC Anesthesiol. 2022 Apr 6;22(1):100. doi: 10.1186/s12871-022-01615-7.
In recent years, high flow nasal oxygen (HFNO) has been widely used in clinic, especially in perioperative period. Many studies have discussed the role of HFNO in pre- and apneic oxygenation, but their results are controversial. Our study aimed to examine the effectiveness of HFNO in pre- and apneic oxygenation by a meta-analysis of RCTs.
EMBASE, PUBMED, and COCHRANE LIBRARY databases were searched from inception to July 2021 for relevant randomized controlled trails (RCTs) on the effectiveness of HFNO versus standard facemask ventilation (FMV) in pre- and apenic oxygenation. Studies involving one of the following six indicators: (1) Arterial oxygen partial pressure (PaO), (2) End expiratory oxygen concentration (EtO), (3) Safe apnoea time, (4) Minimum pulse oxygen saturation (SpO), (5) Oxygenation (O) desaturation, (6) End expiratory carbon dioxide (EtCO) or Arterial carbon dioxide partial pressure(PaCO) were included. Due to the source of clinical heterogeneity in the observed indicators in this study, we adopt random-effects model for analysis, and express it as the mean difference (MD) or risk ratio (RR) with a confidence interval of 95% (95%CI). We conducted a risk assessment of bias for eligible studies and assessed the overall quality of evidence for each outcome.
Fourteen RCTs and 1012 participants were finally included. We found the PaO was higher in HFNO group than FMV group with a MD (95% CI) of 57.38 mmHg (25.65 to 89.10; p = 0.0004) after preoxygenation and the safe apnoea time was significantly longer with a MD (95% CI) of 86.93 s (44.35 to 129.51; p < 0.0001) during anesthesia induction. There were no significant statistical difference in the minimum SpO, CO accumulation, EtO and O desaturation rate during anesthesia induction between the two groups.
This systematic review and meta-analysis suggests that HFNO should be considered as an oxygenation tool for patients during anesthesia induction. Compared with FMV, continuous use of HFNO during anesthesia induction can significantly improve oxygenation and prolong safe apnoea time in surgical patients.
近年来,高流量鼻氧(HFNO)在临床上得到了广泛应用,尤其是在围手术期。许多研究探讨了 HFNO 在预给氧和无通气期的作用,但结果存在争议。我们的研究旨在通过对 RCT 的荟萃分析来检验 HFNO 在预给氧和无通气期的有效性。
从建库到 2021 年 7 月,我们在 EMBASE、PUBMED 和 Cochrane 图书馆数据库中检索了有关 HFNO 与标准面罩通气(FMV)在预给氧和无通气期氧合效果的随机对照试验(RCT)的相关研究。研究纳入了以下 6 个指标中的一个:(1)动脉氧分压(PaO),(2)呼气末氧浓度(EtO),(3)安全无通气时间,(4)最小脉搏血氧饱和度(SpO),(5)氧合(O)下降,(6)呼气末二氧化碳(EtCO)或动脉二氧化碳分压(PaCO)。由于本研究中观察指标的临床异质性来源,我们采用随机效应模型进行分析,并表示为均值差(MD)或风险比(RR),置信区间为 95%(95%CI)。我们对合格研究进行了偏倚风险评估,并对每个结局的总体证据质量进行了评估。
最终纳入 14 项 RCT 和 1012 名参与者。我们发现,HFNO 组在预给氧后 PaO 高于 FMV 组,MD(95%CI)为 57.38mmHg(25.65 至 89.10;p=0.0004),麻醉诱导时安全无通气时间明显延长,MD(95%CI)为 86.93s(44.35 至 129.51;p<0.0001)。两组在麻醉诱导期间最低 SpO、CO 蓄积、EtO 和 O 下降率无统计学差异。
本系统评价和荟萃分析表明,HFNO 应被视为麻醉诱导期间患者的氧合工具。与 FMV 相比,在手术患者的麻醉诱导期间持续使用 HFNO 可显著改善氧合并延长安全无通气时间。